Skip to main content
All lobbying filings

MARSHALL & POPP, LLC

Lobbying for GENENTECH, INC. · Biotechnology company.

 Filing 1st Quarter - Report
Reporting period
1st Quarter 2025
Jan 1 - Mar 31 · Posted Apr 21, 2025
Income
$60,000.00
What the client paid this registrant for the period.
Client based in
District of Columbia

Official filing document

 Lobbyists on this filing 2
  • HAZEN CLAY MARSHALL
    Previously held: Policy Director-Senate Majority Leader Mitch McConnell; Staff Director, Senate Budget Committee-Senator Don Nickles; Deputy Chief of Staff/Economist, Office of Assistant Majority Leader-Senator Don Nickles; Legislative Assistant-Senator Don Nickles
  • MONICA POPP
    Previously held: Chief of Staff/Deputy Chief of Staff, Office of Senate Republican Whip John Cornyn; Professional Staff Member, U.S. House of Representatives-Energy & Commerce Committee; Legislative Assistant, Senator Jim DeMint

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 5
  • Centers For Medicare and Medicaid Services (CMS)
  • Food & Drug Administration (FDA)
  • Health & Human Services, Dept of (HHS)
  • HOUSE OF REPRESENTATIVES
  • SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Bills named in this filing 4
  • HR 1492
    To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
  • HR 2882
    Further Consolidated Appropriations Act, 2024
  • HCONRES 14
    Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appro…
  • SCONRES 7
    An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal ye…
 Lobbying activity 3
Pharmacy

Issues related to prescription drug value, including H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; and implementation of the Inflation Reduction Act (PL 117-169). Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including H.R. 2882, FY2024 Further Consolidated Appropriations Act. Issues related to the 340B program.

Copyright/Patent/Trademark

Issues related to tariff and trade policy.

Trade (domestic/foreign)

Issues related to budget reconciliation, including H.Con.Res. 14 and S.Con.Res. 7.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem